9t9m: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
No edit summary
OCA (talk | contribs)
No edit summary
 
Line 1: Line 1:
'''Unreleased structure'''


The entry 9t9m is ON HOLD
==Tilvestamab Fab bound to the anti-Fab nanobody==
<StructureSection load='9t9m' size='340' side='right'caption='[[9t9m]], [[Resolution|resolution]] 3.09&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[9t9m]] is a 3 chain structure with sequence from [https://en.wikipedia.org/wiki/Mus_sp. Mus sp.]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=9T9M OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=9T9M FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 3.09&#8491;</td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=9t9m FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=9t9m OCA], [https://pdbe.org/9t9m PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=9t9m RCSB], [https://www.ebi.ac.uk/pdbsum/9t9m PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=9t9m ProSAT]</span></td></tr>
</table>
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
AXL is a receptor tyrosine kinase with a significant role in various biological processes and important medical implications, particularly in cancer. AXL transduces signals from the extracellular environment into the cytoplasm by binding to its ligand, growth arrest-specific protein 6 (GAS6). Activation of AXL leads to autophosphorylation of its intracellular domain and subsequent activation of downstream signaling pathways involved in cell proliferation, migration, differentiation, and survival. Tilvestamab (also known as BGB149) is a first-in-class, humanized, therapeutic anti-AXL function-blocking monoclonal antibody. We carried out a structural characterization of the AXL-tilvestamab complex using both negative-stain and cryogenic transmission electron microscopy as well as synchrotron small-angle X-ray scattering. While AXL-Fc was highly elongated and formed large heterogeneous complexes with the full antibody, homogeneous samples for structural studies could be made using the monomeric soluble AXL extracellular domain, the Fab fragment of tilvestamab, and an anti-Fab nanobody. Both SAXS and cryo-EM confirmed successful complex formation between the three proteins, and a low-resolution 3D model for the tilvestamab-AXL complex is presented. The data allow for sample optimization for high-resolution structural biology, as well as designing mutations that could alter binding affinity and specificity.


Authors: Lopez, A.J., Christakou, E., Kursula, P.
Structural Analysis of Tilvestamab in Complex with AXL.,Christakou E, Lopez AJ, Muruganandam G, Micklem D, Lorens JB, Kursula P ACS Omega. 2025 Dec 22;11(1):1874-1882. doi: 10.1021/acsomega.5c10003. , eCollection 2026 Jan 13. PMID:41552498<ref>PMID:41552498</ref>


Description: Tilvestamab Fab bound to the anti-Fab nanobody
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
[[Category: Unreleased Structures]]
</div>
[[Category: Lopez, A.J]]
<div class="pdbe-citations 9t9m" style="background-color:#fffaf0;"></div>
[[Category: Christakou, E]]
== References ==
[[Category: Kursula, P]]
<references/>
__TOC__
</StructureSection>
[[Category: Large Structures]]
[[Category: Mus sp]]
[[Category: Christakou E]]
[[Category: Kursula P]]
[[Category: Lopez AJ]]